Savara's Molgramostim Shows Biomarker Improvements in aPAP Phase 3 Trial
Event summary
- Savara presented new biomarker data from the IMPALA-2 Phase 3 trial of molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS 2026 International Conference.
- Molgramostim significantly improved pulmonary gas transfer and reduced levels of LDH, CYFRA 21-1, and KL-6 biomarkers compared to placebo.
- Strong correlations were observed between biomarker decreases and improvements in pulmonary gas transfer.
- The trial involved 164 patients randomized to receive either molgramostim or placebo for 48 weeks.
The big picture
Savara's positive Phase 3 trial results for molgramostim represent a significant step forward in the treatment of autoimmune pulmonary alveolar proteinosis, a rare and debilitating lung disease. The strong biomarker correlations with clinical improvements could enhance the drug's value proposition and expedite its path to market. The biopharmaceutical sector continues to focus on rare disease therapies, driven by high unmet needs and favorable regulatory incentives.
What we're watching
- Regulatory Pathway
- Whether the biomarker data will support accelerated regulatory approval for molgramostim.
- Commercialization Strategy
- How Savara plans to position molgramostim in the rare disease market given the positive trial results.
- Competitive Landscape
- The potential impact of these results on competing therapies for aPAP.